Connect Biopharma Holdings Limited
CNTB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $26,033 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $988 | $1,031 | $0 |
| Gross Profit | $26,033 | -$988 | -$1,031 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $29,256 | $51,913 | $95,260 | $81,343 |
| G&A Expenses | $19,229 | $15 | $20,367 | $19,227 |
| SG&A Expenses | $19,229 | $13,527 | $20,367 | $19,227 |
| Sales & Mktg Exp. | $0 | $13,512 | $0 | $0 |
| Other Operating Expenses | $0 | -$4,354 | -$940 | -$2,983 |
| Operating Expenses | $48,485 | $62,074 | $114,686 | $97,587 |
| Operating Income | -$22,452 | -$62,074 | -$117,662 | -$99,152 |
| % Margin | -86.2% | – | – | – |
| Other Income/Exp. Net | $7,047 | $2,691 | -$404 | -$103,214 |
| Pre-Tax Income | -$15,405 | -$59,383 | -$116,118 | -$204,939 |
| Tax Expense | $223 | $120 | $298 | $266 |
| Net Income | -$15,628 | -$59,503 | -$116,415 | -$205,205 |
| % Margin | -60% | – | – | – |
| EPS | -0.28 | -1.08 | -14.5 | -25 |
| % Growth | 74.1% | 92.6% | 42% | – |
| EPS Diluted | -0.28 | -1.08 | -14.5 | -25 |
| Weighted Avg Shares Out | 55,213 | 55,067 | 55,044 | 52,273 |
| Weighted Avg Shares Out Dil | 55,213 | 55,067 | 55,044 | 52,273 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,453 | $5 | $1,565 | $98 |
| Interest Expense | $0 | $0 | $21 | $7 |
| Depreciation & Amortization | $660 | $988 | $1,014 | $641 |
| EBITDA | -$21,792 | -$58,372 | -$117,030 | -$201,718 |
| % Margin | -83.7% | – | – | – |